or Try an Advanced Search...

    Technical Analysis for STTK - Shattuck Labs, Inc.

    Grade Last Price % Change Price Change
    C 8.16 -3.77% -0.32
    STTK closed down 3.77 percent on Wednesday, May 15, 2024, on 1.64 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical STTK trend table...
    Date Alert Name Type % Chg
    MACD Bearish Centerline Cross Bearish 0.00%
    Slingshot Bullish Bullish Swing Setup 0.00%
    Calm After Storm Range Contraction 0.00%
    Stochastic Reached Oversold Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Below Lower BB Weakness 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Older End-of-Day Signals for STTK ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 20 hours ago
    Down 3% about 21 hours ago
    Expansion Pivot Sell Entry about 21 hours ago
    Fell Below Previous Day's Low about 21 hours ago
    60 Minute Opening Range Breakdown about 21 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    STTK Chart by TradingView
    Basic chart:

    Profile

    Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Life Sciences Solid Tumors Autoimmune Disease Treatment Of Cancer Lymphoma Clinical Research Clinical Trial Ovarian Cancer Advanced Solid Tumors Clinical Pharmacology Treatment Of Ovarian Cancer

    Is STTK a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 14 Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at th...
    May 7 What Makes Shattuck Labs (STTK) a New Buy Stock
    May 7 Does Shattuck Labs (STTK) Have the Potential to Rally 34.17% as Wall Street Analysts Expect?
    May 4 Shattuck Labs First Quarter 2024 Earnings: Beats Expectations
    May 4 Shattuck Labs Inc (STTK) Reports First Quarter 2024 Financial Results
    May 2 Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates
    May 2 Shattuck Labs GAAP EPS of -$0.37, revenue of $1.11M
    May 2 Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
    Apr 18 Owning 36% shares,institutional owners seem interested in Shattuck Labs, Inc. (NASDAQ:STTK),
    Apr 9 Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
    See more STTK news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.76
    52 Week Low 1.3301
    Average Volume 351,735
    200-Day Moving Average 5.71
    50-Day Moving Average 9.53
    20-Day Moving Average 10.17
    10-Day Moving Average 10.24
    Average True Range 0.90
    RSI (14) 34.21
    ADX 31.35
    +DI 14.38
    -DI 26.76
    Chandelier Exit (Long, 3 ATRs) 9.07
    Chandelier Exit (Short, 3 ATRs) 10.59
    Upper Bollinger Bands 11.79
    Lower Bollinger Band 8.55
    Percent B (%b) -0.12
    BandWidth 31.83
    MACD Line -0.03
    MACD Signal Line 0.26
    MACD Histogram -0.2864
    Fundamentals Value
    Market Cap 384.63 Million
    Num Shares 47.1 Million
    EPS -2.24
    Price-to-Earnings (P/E) Ratio -3.64
    Price-to-Sales 323.03
    Price-to-Book 3.76
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 9.93
    Resistance 3 (R3) 10.05 9.56 9.64
    Resistance 2 (R2) 9.56 9.11 9.51 9.54
    Resistance 1 (R1) 8.86 8.83 8.62 8.75 9.44
    Pivot Point 8.38 8.38 8.26 8.33 8.38
    Support 1 (S1) 7.68 7.93 7.44 7.57 6.88
    Support 2 (S2) 7.20 7.65 7.14 6.78
    Support 3 (S3) 6.50 7.20 6.68
    Support 4 (S4) 6.39